And just like that, it’s over. Bristol Myers Squibb Co. on Jan. 1 confirmed what many suspected, that FDA approval for lisocabtagene maraleucel (liso-cel) did not happen by the Dec. 31 deadline, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback